# Neuralink Corp. — Healthcare Investment Intelligence

> other · Series C+. MedFuel Intel profile as of 2026-06-12.

Neuralink has received over $158 million in funding by 2019, including $100 million from Elon Musk, and has continued to raise significant capital in subsequent rounds, supporting advanced development of implantable brain-computer interfaces with human clinical trials underway.[1] The company received FDA approval in May 2023 and implanted its first human patient in January 2024, indicating progression beyond early-stage funding.[3]

## Key facts (as of 2026-06-12)
- Sector: other
- Stage: Series C+
- Website: https://neuralink.com

## MedFuel assessment
- Intelligence score: 0/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/neuralink-12. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.